Immunotherapy in Metastatic Brain Tumors: Mechanisms, Challenges, and Opportunities for Neurosurgical Integration: A 10-Year Narrative Review
Biomedicine Hub · 22.05.2026 · 11 (1) · 119-131
DOI: 10.1159/000552630 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomedicine Hub, online erschienen am 22.05.2026. Verfasst von Henry Freeman und 5 weiteren Autor:innen. Beteiligte Einrichtung: Michigan State University, East Lansing, MI, USA. Die Arbeit nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background: Brain metastases are the most common intracranial malignancy in adults and represent a major source of neurologic morbidity despite advances in surgery and radiotherapy. Immune checkpoint inhibitors (ICIs) have transformed systemic cancer therapy and are increasingly demonstrating intracranial activity, challenging the long-standing view of the central nervous system as an immune-privileged site. Summary: This narrative review synthesizes mechanistic, translational, and clinical evidence from the past decade examining immunotherapeutic strategies for metastatic brain tumors. We review the neuroimmune microenvironment of brain metastases, including blood-brain and blood-tumor barrier remodeling, myeloid and lymphoid immune niches, and factors that modulate intracranial immune responses. Clinical data supporting the use of ICIs, combination strategies with stereotactic radiosurgery and anti-angiogenic agents, and emerging cellular, viral, and locoregional immunotherapies are discussed, with attention to patterns of intracranial response, resistance, and toxicity. We further examine key challenges unique to the CNS, including corticosteroid-associated immunosuppression and immune-related imaging ambiguity. Throughout, we emphasize the expanding role of neurosurgeons in precision neuro-immuno-oncology through tissue-based discovery, perioperative treatment coordination, steroid-sparing strategies, and development of locoregional delivery platforms. Key Messages: Immunotherapy has meaningful intracranial activity in selected patients with brain metastases but remains constrained by CNS-specific biological and clinical barriers. Integrating immunotherapy into neurosurgically centered, tissue-driven care pathways are essential for advancing precision treatment and improving neurologic outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Michigan State University, East Lansing, MI, USA.
- Michigan State University College of Human Medicine, East Lansing, MI, USA.
- Noorda College of Osteopathic Medicine, Brigham Young University, Provo, UT, USA.
- Department of Neurosurgery, Jamaica Hospital Medical Center, New York, NY, USA.
- Department of Neurosurgery, University of Michigan, Ann Arbor, MI, USA.
Zitieren
APA
Freeman, H., Baloi, D., Rawson, C., Kaur, S., Pahlevani, M., & Karsy, M. (2026). Immunotherapy in Metastatic Brain Tumors: Mechanisms, Challenges, and Opportunities for Neurosurgical Integration: A 10-Year Narrative Review. Biomedicine Hub, 11(1), 119-131. https://doi.org/10.1159/000552630
Vancouver
Freeman H, Baloi D, Rawson C, Kaur S, Pahlevani M, Karsy M. Immunotherapy in Metastatic Brain Tumors: Mechanisms, Challenges, and Opportunities for Neurosurgical Integration: A 10-Year Narrative Review. Biomedicine Hub. 2026;11(1):119-131. doi:10.1159/000552630
BibTeX
@article{Freeman2026,
author = {Freeman, Henry and Baloi, Denise and Rawson, Clayton and Kaur, Sanehdeep and Pahlevani, Mehrdad and Karsy, Michael},
title = {Immunotherapy in Metastatic Brain Tumors: Mechanisms, Challenges, and Opportunities for Neurosurgical Integration: A 10-Year Narrative Review},
journal = {Biomedicine Hub},
year = {2026},
volume = {11},
number = {1},
pages = {119--131},
doi = {10.1159/000552630}
}
EUVIMED